1

Urology Case Studies

www.armune.com

UROLOGY CASE STUDY  

History of Present Illness (HPI) Presents with chief complaint of: •  Increased urinary frequency • Painful urination

Medical History • Hyperlipidemia • Erectile Dysfunction • Negative biopsy 3 years ago

Family History • Father diagnosed with prostate cancer

at 64

Clinical Assessment •  Key factors to consider? •  Severity/duration of

symptoms? •  Differential diagnosis?

Patient: Doug* Age: 62 68

Most Recent PSA Score: 4.6  

Test Results PSA tested annually since age 52. Scores range from 2.3 – 4.9

Clinical Decision •  Change in follow-up/

monitoring? •  Follow-up labs? •  Imaging? •  Biopsy?

 

*Hypothetical patient profile

What is APIFINY®? APIFINY is the only cancer specific, non-PSA blood test that may aid clinicians in the assessment of risk for the presence of prostate cancer.

When should I order APIFINY? APIFINY may be used in men who have an elevated PSA (>2.5 ng/ml) and are considering a prostate biopsy.

Why should I order APIFINY? APIFINY measures certain specific biological markers that may provide you with additional insight to aid in a clinical decision for determining your patient’s risk of prostate cancer.

UROLOGY CASE STUDY  

Patient: George* Age: 50

History of Present Illness (HPI) Presents upon referral from primary care: •  Nocturia (slightly worse over past year) • Normal digital rectal exam (DRE) • Normal urinalysis (UA)

Medical History • Hypertension (HTN) • Erectile Dysfunction

Family History • Father died of a heart attack at age 60

Clinical Assessment •  Key factors to consider? •  Severity/duration of

symptoms? •  Differential diagnosis?

Test Results PSA tested annually since age 42. Scores range from 2.6 – 3.7

54

Most Recent PSA Score: 4.5  

Clinical Decision •  Change in follow-up/

monitoring? •  Follow-up labs? •  Imaging? •  Biopsy?

 

*Hypothetical patient profile

What is APIFINY®? APIFINY is the only cancer specific, non-PSA blood test that may aid clinicians in the assessment of risk for the presence of prostate cancer.

When should I order APIFINY? APIFINY may be used in men who have an elevated PSA (>2.5 ng/ml) and are considering a prostate biopsy.

Why should I order APIFINY? APIFINY measures certain specific biological markers that may provide you with additional insight to aid in a clinical decision for determining your patient’s risk of prostate cancer.

UROLOGY CASE STUDY  

Patient: Robert* Age: 45

History of Present Illness (HPI) Presents for routine annual exam: • Mildly enlarged prostate gland • Negative review of symptoms (ROS)

Medical History • Hypertension (HTN) • Vasectomy 5 years ago • Negative biopsy 2 years ago

Family History • Grandfather diagnosed with prostate

cancer at 54

Clinical Assessment •  Key factors to consider? •  Severity/duration of

symptoms? •  Differential diagnosis?

Test Results PSA tested annually since age 40. Scores range from 2.8 – 4.7

Most Recent PSA Score: 4.6  

22

Clinical Decision •  Change in follow-up/

monitoring? •  Follow-up labs? •  Imaging? •  Biopsy?

 

*Hypothetical patient profile

What is APIFINY®? APIFINY is the only cancer specific, non-PSA blood test that may aid clinicians in the assessment of risk for the presence of prostate cancer.

When should I order APIFINY? APIFINY may be used in men who have an elevated PSA (>2.5 ng/ml) and are considering a prostate biopsy.

Why should I order APIFINY? APIFINY measures certain specific biological markers that may provide you with additional insight to aid in a clinical decision for determining your patient’s risk of prostate cancer.

UROLOGY CASE STUDY  

Patient: Peter* Age: 55

History of Present Illness (HPI) Presents upon referral from primary care: • Denies any symptoms (negative ROS) • Normal urinalysis (UA) • Mildly enlarged prostate gland

Medical History • Hypertension (HTN) • Negative prostate biopsy 5 years prior

Family History • No known history of prostate cancer

Clinical Assessment •  Key factors to consider? •  Severity/duration of

symptoms? •  Differential diagnosis?

Test Results PSA tested annually since age 42. Scores range from 2.3 – 4.5

92

Most Recent PSA Score: 4.2  

Clinical Decision •  Change in follow-up/

monitoring? •  Follow-up labs? •  Imaging? •  Biopsy?

 

*Hypothetical patient profile

What is APIFINY®? APIFINY is the only cancer specific, non-PSA blood test that may aid clinicians in the assessment of risk for the presence of prostate cancer.

When should I order APIFINY? APIFINY may be used in men who have an elevated PSA (>2.5 ng/ml) and are considering a prostate biopsy.

Why should I order APIFINY? APIFINY measures certain specific biological markers that may provide you with additional insight to aid in a clinical decision for determining your patient’s risk of prostate cancer.

www.armune.com 6

APIFINY® – Results Interpretation

Lower risk of prostate cancer. Score not consistent with prostate cancer. “In the most recent peer-reviewed published study on Apifiny1, approximately 9 out of 10 men like you, with a score of less than 59, were cancer free.” Potential clinical decision2: Combine with other clinical information to determine next steps. Continue routine clinical monitoring.

Higher risk of prostate cancer. Score consistent with prostate cancer. “In the most recent peer-reviewed published study on Apifiny1, approximately 1 out of 3 men like you, with a score of 59 or above, had prostate cancer. You may be at higher risk.” Potential clinical decision2: Combine with other clinical information to determine next steps. Develop an individualized patient management plan and consider a prostate biopsy

APIFINY® Prostate Cancer

Risk Assessment

Lower Risk

Higher Risk

0 59 100

1. Translational Oncology, April 2015, Volume 8 Number 2: 106-111 2. Physician utilization market research (2015)